Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Myokardia Inc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Myokardia Inc (MYOK) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q3 2020

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MYOK/competitors
https://api.csimarket.com/api/v1/companies/MYOK/relationships
https://api.csimarket.com/api/v1/companies/MYOK/similar
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API

Myokardia Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Myokardia Inc - - - No
High-Confidence Competitors (104) 59% 67% 47% 61%

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

MYOK Stock Performance relative to its Competitors

MYOK Competitors (weighted) Percent change over the selected range

Myokardia Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
34.1%beat U.S.A. 500
High-Confidence
(29 of 85)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
Myokardia Inc - -
Competitors combined (0) 40.4% 63.2%
High-Confidence Competitors (85) 40.4% 63.2%
Similar-Size Competitors (0) 40.4% 63.2%
Similar Growth & Profitability (0) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Myokardia Inc's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

MYOK Stock Performance relative to High-Confidence Competitors

MYOK High-Confidence Competitors (equal-weighted, 108) Percent change over the selected range
Competitor data is not yet available for Myokardia Inc.

Myokardia Inc's Competitors Named by the Company

Competitive relationships identified from Myokardia Inc reports and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
Actinium Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Agentix Corp Company report 85% 2022 to 2026 3
Monopar Therapeutics Inc Company report 85% 2022 to 2026 3
Cadrenal Therapeutics Inc Company report 85% 2022 to 2026 3
Qsam Biosciences Inc Company report 85% 2022 to 2026 3
Shattuck Labs Inc Company report 85% 2022 to 2026 3
Spyre Therapeutics Inc Company report 85% 2022 to 2026 3
Protagonist Therapeutics inc Company report 85% 2022 to 2026 3
Adaptimmune Therapeutics Plc Company report 85% 2022 to 2026 3
AbbVie Inc. Company report 85% 2022 to 2026 3
AstraZeneca plc Company report 85% 2022 to 2026 3
Amgen, Inc. Company report 85% 2022 to 2026 3
Briacell Therapeutics Corp Company report 85% 2022 to 2026 3
Fate Therapeutics Inc Company report 85% 2022 to 2026 3
Sana Biotechnology Inc Company report 85% 2022 to 2026 3
Sellas Life Sciences Group Inc Company report 85% 2022 to 2026 3
Can fite Biopharma Ltd Company report 85% 2022 to 2026 3
Intra cellular Therapies Inc Company report 85% 2022 to 2026 3
Nuvalent Inc Company report 85% 2022 to 2026 3
Cell Source Inc Company report 85% 2022 to 2026 3
Elicio Therapeutics Inc Company report 85% 2022 to 2026 3
Vincerx Pharma Inc Company report 85% 2022 to 2026 3
Gsk Plc Company report 85% 2022 to 2026 3
Allogene Therapeutics Inc Company report 85% 2022 to 2026 3
Pfizer Inc. Company report 85% 2022 to 2026 3
Johnson and Johnson Company report 85% 2022 to 2026 3
Takeda Pharmaceutical Company Limited Company report 85% 2022 to 2026 3
Gilead Sciences, Inc. Company report 85% 2022 to 2026 3
Sanofi S.A. Company report 85% 2022 to 2026 3
Fusion Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Marker Therapeutics inc Company report 85% 2022 to 2026 3
Eli Lilly and Company Company report 85% 2022 to 2026 3
Merck and Co Inc Company report 85% 2022 to 2026 3
Corvus Pharmaceuticals, Inc. Company report 85% 2022 to 2026 3
Definium Therapeutics Inc Company report 85% 2022 to 2026 3
Atlantic Coastal Acquisition Corp Ii Company report 85% 2022 to 2026 3
Sunshine Biopharma Inc Company report 85% 2022 to 2026 3
Silexion Therapeutics Corp Company report 85% 2022 to 2026 3
Redwoods Acquisition Corp Company report 85% 2022 to 2026 3
Tradeup Acquisition Corp Company report 85% 2022 to 2026 3
Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Myokardia Inc's named competitors require a Commercial License.

Methodology: relationships are extracted from Myokardia Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.

Get the full CSIMarket dataset: Subscribe API Connect Your AI